Lauren Santye, Assistant Editor

Emicizumab prophylaxis is designed to bring together factors IXa and X to restore the blood clotting process.

Risk of death from MS higher among men in military across 3 successive decades.

HIV rebound detected within 1 day before delivery in 50% of study participants.

Top news of the day from across the health care landscape.

Lebrikizumab is a monoclonal antibody designed to specifically target interleukin 13 for patients with moderate-to-severe atopic dermatitis.

Lebrikizumab is a monoclonal antibody designed to treat atopic dermatitis.

T cell responses in different tumor models are fundamentally similar.

Odefsey label updated to include updated data from clinical trials examining patients who switched from tenofovir disoproxil fumarate-based regimens.

Changes include additional trial data in virologically-suppressed adults with HIV-1 infection.

Study finds greater rate of opioid prescribing among cancer survivors 10 or more years past their cancer diagnosis.

Marc O’Connor, chief operating officer at Curant Health, explains why treating the whole patient rather than just their specific disease is so important.

Andexanet alfa is the first compound being investigated as an antidote for Factor Xa inhibitors.

Hibernating innate lymphoid cells allows inflammation to persist in rheumatoid arthritis.

Top news of the day from across the health care landscape.

Understudied gene provides insight into how liver cancer cells gain the nutrition necessary to proliferate.

Legislative investigation seeks information from 7 drug makers on costs for MS medications.

Novel diabetes biosimilar shows similar safety, efficacy, and immunogenicity to the reference drug.

Brentuximab vedotin under evaluation for the treatment of cutaneous T-cell lymphoma.

The novel strategy could be more effective and less toxic than current chemotherapy drugs treating alternative lengthening telomere cancers.

Incentives for newly covered low-income patients may also reduce long-term costs.

Top news of the day from across the health care landscape.

Pharmacy service was launched 6 years ago to help patients remain adherent to treatment regimens.

Managing chronic pain after a cancer diagnosis remains a challenge.

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer.

Hepatitis C elimination program screens more than 45K individuals in first 2 years of launch.

Top news of the day from across the health care landscape.

A gut microbe may play a role in the treatment of multiple sclerosis in the future.

Research finds that a robust pipeline of PsA agents will put pressure on Cosentyx.

Phase 3 program to examine novel gene therapy that treats the cause of hemophilia A.

Study is the first to provide evidence that proton-coupled amino acid transporters can be elevated in prostate cancer.